Agreements - Novartis (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Agreements disclosures
Revenue from contract with customer	$ 15,375	$ 9,210	$ 67,615	$ 41,864
Deferred revenue	53,811	106,005	53,811	106,005		$ 92,068	$ 110,109
License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer	7,382	$ 2,677	45,247	$ 3,086
Novartis
Collaborative Agreements disclosures
Deferred revenue	2,800		2,800		$ 2,800
Novartis | License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer			2,800
Novartis | Milestone payments plus royalties on the commercial sales
Collaborative Agreements disclosures
Revenue from contract with customer			5,000
Novartis | Future Technological Improvements
Collaborative Agreements disclosures
Deferred revenue	800		800
Maximum | Novartis | Milestone payments plus royalties on the commercial sales
Collaborative Agreements disclosures
Potential milestone payment	$ 199,500		$ 199,500